Eribulin Reduces Aggressiveness in Luminal Breast
Cancer Tumours in the early setting
Objective: To compare
mRNA expression and response
to neoadjuvant
treatment with Eribulin in HER2-negative BC patients
Prat, A., et al.,
SABCS
2015 (abstract P3-07-66).
8
%
21
%
In this study, Eribulin treatment led to
major phenotype shift
from luminal B to luminal A
This opens further possibilities for the
combination of HT +
Eribulin
in selected patients
